<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32209625</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).</ArticleTitle><Pagination><StartPage>e034049</StartPage><MedlinePgn>e034049</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e034049</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2019-034049</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurological disorder characterised by a selective degeneration of motor neurons (MNs). Stem cell transplantation is considered as a promising strategy in neurological disorders therapy and the possibility of inducing bone marrow cells (BMCs) to circulate in the peripheral blood is suggested to investigate stem cells migration in degenerated ALS nerve tissues where potentially repair MN damage. Granulocyte-colony stimulating factor (G-CSF) is a growth factor which stimulates haematopoietic progenitor cells, mobilises BMCs into injured brain and it is itself a neurotrophic factor for MN. G-CSF safety in humans has been demonstrated and many observations suggest that it may affect neural cells. Therefore, we decided to use G-CSF to mobilise BMCs into the peripheral circulation in patients with ALS, planning a clinical trial to evaluate the effect of G-CSF administration in ALS patients compared with placebo.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">STEMALS-II is a phase II multicentre, randomised double-blind, placebo-controlled, parallel group clinical trial on G-CSF (filgrastim) and mannitol in ALS patients. Specifically, we investigate safety, tolerability and efficacy of four repeated courses of intravenous G-CSF and mannitol administered in 76 ALS patients in comparison with placebo (indistinguishable glucose solution 5%). We determine increase of G-CSF levels in serum and cerebrospinal fluid as CD34<sup>+</sup> cells and leucocyte count after treatment; reduction in ALS Functional Rating Scale-Revised Score, forced vital capacity, Scale for Testing Muscle Strength Score and quality of life; the adverse events/reactions during the treatment; changes in neuroinflammation biomarkers before and after treatment.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The study protocol was approved by the Ethics Committee of Azienda Ospedaliera Universitaria 'Citt&#xe0; della Salute e della Scienza', Torino, Italy. Results will be presented during scientific symposia or published in scientific journals.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">Eudract 2014-002228-28.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salamone</LastName><ForeName>Paolina</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9038-7816</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuda</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casale</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1097-1279</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy federico.casale@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrali</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caponnetto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurological Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Maggiore della Carit&#xe0; Hospital, University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Bella</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Sicilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Azienda Ospedaliera Universitaria Modena, St. Agostino-Estense Hospital, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Isabella Laura</ForeName><Initials>IL</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Puglia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarella</LastName><ForeName>Corrado</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oncohematology Division, IEO European Institute of Oncology, IRCCS, University of Milan, Milano, Lombardia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>STEMALS-II Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2014-002228-28</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PVI5M0M1GW</RegistryNumber><NameOfSubstance UI="D000069585">Filgrastim</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069585" MajorTopicYN="N">Filgrastim</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GCS-F</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">haematopoietic stem cells</Keyword><Keyword MajorTopicYN="N">randomised clinical trial</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bombaci</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunetti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cammarosano</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canosa</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calvo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daviddi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Marco</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cugnasco</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grassano</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iazzolino</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ilardi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lauritano</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lomartire</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manera</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solero</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torrieri R Vasta</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilestro</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muccio P Omed&#xe9;</LastName><ForeName>V E</ForeName><Initials>VE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerardi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabona</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bersano</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Marchi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spataro</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scim&#xe8;</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fasano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fini</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessani</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Errico</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarafino</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32209625</ArticleId><ArticleId IdType="pmc">PMC7202695</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2019-034049</ArticleId><ArticleId IdType="pii">bmjopen-2019-034049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Mora G, Moglia C, et al. . Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d'Aosta register. JAMA Neurol 2017;74:1097&#x2013;104.10.1001/jamaneurol.2017.1387</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1387</ArticleId><ArticleId IdType="pmc">PMC5710181</ArticleId><ArticleId IdType="pubmed">28692730</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733&#x2013;48.10.1002/med.21528</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, et al. . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;210.1002/14651858.CD001447</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447</ArticleId><ArticleId IdType="pubmed">17253460</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12.10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C-G, Zhang Y-Z, Wu H-N, et al. . Stem cells: a promising candidate to treat neurological disorders. Neural Regen Res 2018;13:1294&#x2013;304.10.4103/1673-5374.235085</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.235085</ArticleId><ArticleId IdType="pmc">PMC6065243</ArticleId><ArticleId IdType="pubmed">30028342</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan WP, Begley CG, Juttner CA, et al. . Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640&#x2013;4.10.1016/0140-6736(92)90795-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(92)90795-5</ArticleId><ArticleId IdType="pubmed">1371817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonig H, Papayannopoulou T. Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. Methods Mol Biol 2012;904:1&#x2013;14.10.1007/978-1-61779-943-3_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-943-3_1</ArticleId><ArticleId IdType="pmc">PMC3676430</ArticleId><ArticleId IdType="pubmed">22890918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarella C, Ferrero D, Bregni M, et al. . Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991;27:22&#x2013;7.10.1016/0277-5379(91)90052-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0277-5379(91)90052-F</ArticleId><ArticleId IdType="pubmed">1826435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallner S, Peters S, Pitzer C, et al. . The granulocyte-colony stimulating factor has a dual role in neuronal and vascular plasticity. Front Cell Dev Biol 2015;3:48.10.3389/fcell.2015.00048</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2015.00048</ArticleId><ArticleId IdType="pmc">PMC4528279</ArticleId><ArticleId IdType="pubmed">26301221</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006;99:690&#x2013;705.10.1002/jcb.21043</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.21043</ArticleId><ArticleId IdType="pubmed">16888804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;bitz W-R, Kollmar R, Schwaninger M, et al. . Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 2003;34:745&#x2013;51.10.1161/01.STR.0000057814.70180.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000057814.70180.17</ArticleId><ArticleId IdType="pubmed">12624302</ArticleId></ArticleIdList></Reference><Reference><Citation>Solaroglu I, Jadhav V, Zhang JH. Neuroprotective effect of granulocyte-colony stimulating factor. Front Biosci 2007;12:712&#x2013;24.10.2741/2095</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2095</ArticleId><ArticleId IdType="pubmed">17127331</ArticleId></ArticleIdList></Reference><Reference><Citation>Deda H, Inci MC, K&#xfc;rek&#xe7;i AE, et al. . Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18&#x2013;25.10.1080/14653240802549470</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240802549470</ArticleId><ArticleId IdType="pubmed">19012065</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado-Soto AR, Oakley DH, Wichterle H, et al. . Stem cells in the nervous system. Am J Phys Med Rehabil 2014;93:S132&#x2013;44.10.1097/PHM.0000000000000111</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000000111</ArticleId><ArticleId IdType="pmc">PMC4197112</ArticleId><ArticleId IdType="pubmed">24800720</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Xiao Q, et al. . Wild-Type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2006;103:16021&#x2013;6.10.1073/pnas.0607423103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607423103</ArticleId><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasiene J, Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011;2011:1&#x2013;7.10.1155/2011/718987</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/718987</ArticleId><ArticleId IdType="pmc">PMC3135155</ArticleId><ArticleId IdType="pubmed">21766027</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011;10:253&#x2013;63.10.1016/S1474-4422(11)70015-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti S, Locatelli F, Donadoni C, et al. . Wild-Type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 2004;127:2518&#x2013;32.10.1093/brain/awh273</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh273</ArticleId><ArticleId IdType="pubmed">15469951</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron P, Bussini S, Cardin V, et al. . Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005;32:541&#x2013;4.10.1002/mus.20376</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20376</ArticleId><ArticleId IdType="pubmed">15962273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail A, Cooper-Knock J, Highley JR, et al. . Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9orf72. J Neurol Neurosurg Psychiatry 2013;84:79&#x2013;87.10.1136/jnnp-2012-303326</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303326</ArticleId><ArticleId IdType="pubmed">23085936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H-M, Zhou H, Hong J-S. Nadph oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci 2012;33:295&#x2013;303.10.1016/j.tips.2012.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2012.03.008</ArticleId><ArticleId IdType="pmc">PMC3477578</ArticleId><ArticleId IdType="pubmed">22503440</ArticleId></ArticleIdList></Reference><Reference><Citation>England TJ, Sprigg N, Alasheev AM, et al. . Granulocyte-Colony stimulating factor (G-CSF) for stroke: an individual patient data meta-analysis. Sci Rep 2016;6:3656710.1038/srep36567</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36567</ArticleId><ArticleId IdType="pmc">PMC5109224</ArticleId><ArticleId IdType="pubmed">27845349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai S-T, Chu S-C, Liu S-H, et al. . Neuroprotection of granulocyte colony-stimulating factor for early stage Parkinson's disease. Cell Transplant 2017;26:409&#x2013;16.10.3727/096368916X694247</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368916X694247</ArticleId><ArticleId IdType="pmc">PMC5657704</ArticleId><ArticleId IdType="pubmed">27938485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitzer C, Kr&#xfc;ger C, Plaas C, et al. . Granulocyte-Colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008;131:3335&#x2013;47.10.1093/brain/awn243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn243</ArticleId><ArticleId IdType="pmc">PMC2639207</ArticleId><ArticleId IdType="pubmed">18835867</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E, Savchenko E, Jaronen M, et al. . Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2011;8:7410.1186/1742-2094-8-74</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-74</ArticleId><ArticleId IdType="pmc">PMC3146845</ArticleId><ArticleId IdType="pubmed">21711557</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittgen T, Pitzer C, Plaas C, et al. . Granulocyte-Colony stimulating factor (G-CSF) improves motor recovery in the rat impactor model for spinal cord injury. PLoS One 2012;7:e2988010.1371/journal.pone.0029880</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029880</ArticleId><ArticleId IdType="pmc">PMC3257226</ArticleId><ArticleId IdType="pubmed">22253813</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson FL, Heerssen HM, Bhattacharyya A, et al. . Neurotrophins use the ERK5 pathway to mediate a retrograde survival response. Nat Neurosci 2001;4:981&#x2013;8.10.1038/nn720</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn720</ArticleId><ArticleId IdType="pubmed">11544482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamezaki K, Shimoda K, Numata A, et al. . Roles of STAT3 and ERK in G-CSF signaling. Stem Cells 2005;23:252&#x2013;63.10.1634/stemcells.2004-0173a</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2004-0173a</ArticleId><ArticleId IdType="pubmed">15671148</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Klebe D, Doycheva D, et al. . G-Csf ameliorates neuronal apoptosis through GSK-3&#x3b2; inhibition in neonatal hypoxia-ischemia in rats. Exp Neurol 2015;263:141&#x2013;9.10.1016/j.expneurol.2014.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.10.004</ArticleId><ArticleId IdType="pmc">PMC4262712</ArticleId><ArticleId IdType="pubmed">25448005</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki R, Tanaka M, Fukunaga M, et al. . Restoration of microglial function by granulocyte-colony stimulating factor in ALS model mice. J Neuroimmunol 2010;229:51&#x2013;62.10.1016/j.jneuroim.2010.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.07.002</ArticleId><ArticleId IdType="pubmed">20659772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Kr&#xfc;ger C, Steigleder T, et al. . The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:2083&#x2013;98.10.1172/JCI23559</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23559</ArticleId><ArticleId IdType="pmc">PMC1172228</ArticleId><ArticleId IdType="pubmed">16007267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch F, Kr&#xfc;ger C, Schneider A. The receptor for granulocyte-colony stimulating factor (G-CSF) is expressed in radial glia during development of the nervous system. BMC Dev Biol 2008;8:3210.1186/1471-213X-8-32</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-213X-8-32</ArticleId><ArticleId IdType="pmc">PMC2329616</ArticleId><ArticleId IdType="pubmed">18371196</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Kikuchi H, Ishizu T, et al. . Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006;65:816&#x2013;25.10.1097/01.jnen.0000232025.84238.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000232025.84238.e1</ArticleId><ArticleId IdType="pubmed">16896315</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, et al. . EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol 2012;19:360&#x2013;75.10.1111/j.1468-1331.2011.03501.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiviniemi V, Korhonen V, Kortelainen J, et al. . Real-Time monitoring of human blood-brain barrier disruption. PLoS One 2017;12:e017407210.1371/journal.pone.0174072</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174072</ArticleId><ArticleId IdType="pmc">PMC5358768</ArticleId><ArticleId IdType="pubmed">28319185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarella C, Rutella S, Gualandi F, et al. . Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy 2010;12:50&#x2013;9.10.3109/14653240903300682</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14653240903300682</ArticleId><ArticleId IdType="pubmed">19878077</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, La Bella V, et al. . Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011;43:189&#x2013;95.10.1002/mus.21851</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21851</ArticleId><ArticleId IdType="pubmed">21254083</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrali G, Casale F, Salamone P, et al. . Nadph oxidase (Nox2) activity is a modifier of survival in ALS. J Neurol 2014;261:2178&#x2013;83.10.1007/s00415-014-7470-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7470-0</ArticleId><ArticleId IdType="pubmed">25178511</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirzagar N, Nafissi S, Tafakhori A, et al. . Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study of Iranian patients. J Clin Neurol 2015;11:164&#x2013;71.10.3988/jcn.2015.11.2.164</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2015.11.2.164</ArticleId><ArticleId IdType="pmc">PMC4387482</ArticleId><ArticleId IdType="pubmed">25851895</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen S, Budeus B, Peters S, et al. . Biomarker supervised G-CSF (filgrastim) response in ALS patients. Front Neurol 2018;9:97110.3389/fneur.2018.00971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00971</ArticleId><ArticleId IdType="pmc">PMC6275232</ArticleId><ArticleId IdType="pubmed">30534107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;9.10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>